First-time authors logo

Further to our commitment for supporting young immunologists, the EJI editorial team has introduced editorial policy to guarantee peer-review and in-depth feedback for articles submitted by first-time first authors/first-time corresponding authors. If you are a first-time first author/corresponding author please contact EJI editorial office [email protected] or mention this in the Cover Letter when submitting your manuscript. In addition, EJI is highlighting the work of first-time first authors as well as first-time corresponding authors. Join us and celebrate the outstanding work of early career immunologists around the globe!

Charlotte Vetter and Jakob Schieb

The impact of IL-10 and IL-17 on myeloid-derived suppressor cells in vitro and in vivo in a murine model of asthma
Eur J Immunol. DOI 10.1002/eji.202350785
First published 23 April 2024
Full text I PDF

Photos of first-time authors Charlotte Vetter and Jakob Schieb

"Both of us are immensely proud to be the first authors of this paper and grateful for the opportunity to publish in the esteemed European Journal of Immunology. Conducting this study and preparing the paper have been challenging and enlightening. We are thankful for this remarkable laboratory experience, which was an invaluable journey alongside our medical studies. For us, this publication will pave the way for our medical dissertation, marking a significant milestone in our journey as both scientists and doctors.

In our research, we uncovered new insights into MDSCs' anti-inflammatory role in lung diseases like asthma together with our team, following the overarching goal of a new therapeutic approach for asthma treatment. This study especially underscores the crucial role of IL-17, as it influences the quantity and function of MDSCs, as well as pulmonary inflammation. We are excited to see what the future holds."

Theresa von Heyl

Loss of αβ but not γδ T cells in chickens causes a severe phenotype
Eur J Immunol. DOI 10.1002/eji.202350503
First published 21 September 2023
Full text I PDF

Being a first-time first author is an exciting and transformative experience in my career, as it signifies the culmination of years of hard work, research, and dedication. For sure, this milestone marks the beginning of a promising career in the field of immunology, and it might open doors to new opportunities, and responsibilities. I am very thankful for my co-authors, who supported me throughout the whole process, especially my supervisor, Benjamin Schusser. The findings of our paper gave new insights into T cell subpopulations in chicken. We generated chickens lacking ab or gd T cells by genomic deletion of the constant region of the T cell receptor b or g chain. Surprisingly, our results showed that deletion of ab T cells but not gd T cells resulted in a severe phenotype in chicken, as demonstrated by granulomas, and inflammatory reactions in the spleen and proventriculus. In summary, being a first-time first author represents a significant step forward and the chance to make a lasting impact in the field of immunology.    

Christoph Ratswohl

Having achieved my 1st first authorship makes me proud and I feel very honoured and happy to publish our study in the European Journal of Immunology. This paper is definitely a reward for the hard work during my PhD years and unites obtained skills that I consider as a requirement for good science, thus laying the foundation for future publications. In our study we aimed to develop safer and more effective vaccines by abrogating vaccine antigen binding to human cell receptors. Current market-available vaccine designs do not abolish the interaction with these receptors, which may lead to masking or displacement of the vaccine and to misbalancing of the receptor´s body functions, respectively. As novel vaccine types, which diffuse all over the body, are on the rise, our so-called BIBAX strategy holds promise to improve safety profiles and more potently induces B cell and antibody responses.    

EFIS interview with Christoph Ratswohl:


Luisina Onofrio

"Being the first-time corresponding author means a great deal to my career. It signifies a milestone in my academic journey and gives me the confidence to continue pursuing my research goals. It also means that I am taking on more responsibility and leadership in the lab, which will help me grow as a scientist. I would like to take this opportunity to express my gratitude to my mentor, Eva Acosta-Rodriguez, for her invaluable guidance and support throughout this project. In our study, we demonstrate for the first time that tofacitinib-treated RA patients exhibit an accumulation of T cells with a senescence-associated phenotype. Moreover, the in vitro assays allowed us to precisely determine tofacitinib´s inhibitory effects in the activation, proliferation, effector function, and senescence induction in T cells. These findings providing unprecedented evidences about distinctive impacts according to the T cell differentiation status. We found that Tofacitinib treatment had the greatest impact on memory CD8+ T cells, which play a critical role in controlling the recurrence of viral infections such as herpes zoster. Therefore, our findings open new avenues for the generation of complementary therapies that address the immunosuppressive side effects of JAKi treatment.  We hope that our work will inspire further research in this area and contribute to the advancement of immunology as a whole."

yEFIS interview with Luisina Onofrio:

Sehee Rim

"Starting the MD-PhD program, my aim was to help add important knowledge that could be useful for many people. It is a true honour for me and my co-authors that we could share our results in a renowned journal like the European Journal of Immunology. Publishing my first research paper is a huge inspiration and motivation for pursuing a career in research and academia. Our study describes dynamics of major immune cell populations over time in a human experimental enterotoxigenic Escherichia coli (ETEC) infection model. We used cutting-edge mass cytometry technology allowing a high number of phenotypic and activation markers to be used simultaneously. Our results confirm the plasmablast recirculation and provides new information on MAIT and T cell subset dynamics during ETEC infection. The findings shed new light on the role of human cellular immunity in gut infections and may help guide research for a vaccine against ETEC."

Kirsty R. Field

"Conducting and preparing this manuscript as a first-time first author has been a challenging and rewarding experience. I feel privileged to have had the opportunity to publish my work in a well-respected scientific journal such as the European Journal of Immunology. I am extremely grateful to my co-authors, who provided guidance and support throughout the entire process. This experience has given me a greater appreciation for rigorous and transparent scientific investigation, and valuable insights into what a career in academia may look like. In this study, we explored how pro-inflammatory cytokine stimulation throughout in vitro expansion can enhance Vγ9Vδ2 T cell TCR-dependent and TCR-independent cytotoxicity. These findings further our understanding of how Vγ9Vδ2 T cells target and eliminate transformed or infected cells. The identification of culture conditions capable of driving heightened Vγ9Vδ2 T-cell effector functions may aid in the development of more effective immunotherapies for the treatment of cancers or infectious diseases."

yEFIS interview with Kirsty R. Field:

Jonathan W. Lo

A population of naive-like CD4+ T cells stably polarized to the TH1 lineage
Eur J Immunol. Vol. 52, Iss. 4, 566-581
First published 28 January 2022
Full text I PDF

"In academia, publishing is one of the major criteria upon which we, as academic scientists, are judged on and how we become regarded as experts in our field of research. So therefore, for me to get my PhD work published in such a fantastic and reputable journal as The European Journal of Immunology is brilliant and makes me proud of both my work as a PhD and of its importance in the field of immunology. The findings in my paper are significant as this is the first known mouse line that can trace the ontogeny of T-bet expressed immune cells and therefore help us identify any immune cells that have previously or are currently expressing T-bet. The most significant finding in this paper was the identification of a previously unknown subset of naïve CD4+ T cells which have previously expressed T-bet but displayed the hallmarks both transcriptionally and phenotypically as being naïve. Furthermore, upon both in vitro or in vivo experiments, they were unable to polarise into anything other than a Th1 IFNγ producing CD4+ T cell. Therefore, these T-bet fate mapped naïve CD4+ T cells are predetermined to become a Th1 cell and this has not previously been found before."